A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Peer Review reports

Original Submission
13 Sep 2016	Submitted	Original manuscript
8 Feb 2017	Reviewed	Reviewer Report - Peter Muscarella
12 Feb 2017	Reviewed	Reviewer Report - Yingyong Hou
19 Feb 2017	Reviewed	Reviewer Report - Shunji Takahashi
20 Mar 2017	Author responded	Author comments - Kerry Lynn Reynolds
Resubmission - Version 2
20 Mar 2017	Submitted	Manuscript version 2
16 Jul 2017	Reviewed	Reviewer Report - Shunji Takahashi
30 Aug 2017	Author responded	Author comments - Kerry Lynn Reynolds
Resubmission - Version 3
30 Aug 2017	Submitted	Manuscript version 3
Publishing
4 Sep 2017	Editorially accepted
12 Sep 2017	Article published	10.1186/s12885-017-3641-6

Back to article page